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A dvancements in the treatment of cancer occurring over the past 3 decades have resulted in decreased cancer-related morbidity and mortality, and increased long-term survivorship.
Today, data from billing codes related to cancer patients indicate that cardiovascular (CV) disease (CVD) is the leading cause of death among breast cancer survivors, replacing recurrent cancer or development of a new cancer (1) . In childhood cancer survivors (2, 3) , the risk of CV death is now higher than the actual risk of tumor recurrence (with a reported 7-fold increase in cardiac mortality rate relative to siblings without cancer).
In this paper, we review the cancer therapies and their associated CV events, existing noninvasive imaging study results highlighting methods to detect early evidence of CV injury upon receipt of treatment for cancer, and emerging noninvasive imaging technologies that may further enhance the detection of CV injury. Results of several studies raise the possibility that noninvasive imaging may be useful for identifying CV injury after receipt of cancer treatment.
CARDIOVASCULAR INJURY FROM CANCER TREATMENT
The type and duration of cancer treatment still plays an important role in determining CV injury or toxicity. Cardiovascular toxicity can be caused by: 1) direct injury to or death of cardiac myocytes; 2) stimulation of myocardial fibrosis; 3) provocation of stress induced myocardial ischemia via endothelial dysfunction; 4) vascular injury; 5) myocardial and/or pericardial inflammation; 6) arrhythmogenic or conduction abnormalities; 7) autonomic dysfunction; 8) valvular disease; or 9) exacerbation of known CV risk factors (e.g., hypertension, accelerated atherosclerosis, or Raynaud's syndrome, etc.) (4, 5) . In addition to traditional cardiotoxic agents, such as anthracyclines or radiation-related heart disease, newer therapies including tyrosine kinase inhibitors (6) (7) (8) (9) (10) (11) and even therapies that are not necessarily classified as "chemotherapy" may also promote CV disease or events. For example, the administration of hormone deprivation therapies, which have dramatically reduced cancer recurrence and improved survival in women with breast cancer or men with prostate cancer, are now increasingly associated with CV events (12) (13) (14) (15) (16) . Online Table 1 in the Online Appendix presents a summary of the types of cardiac injuries, the agents that commonly cause these injuries, and noninvasive investigations to determine the extent of these injuries. LVEF by >10% from baseline, or to a value <50% went on to develop heart failure (17) . Today, ERNA is used to identify LV dysfunction from other cardiotoxic agents (17, 18) .
CURRENT CLINICAL NONINVASIVE IMAGING STRATEGIES FOR SCREENING CANCER TREATMENT-RELATED CARDIOTOXICITY
In addition to resting measures of LVEF, investigators have also assessed the utility of ERNA stress-induced changes in LVEF as markers of early anthracycline induced cardiomyopathy. McKillop et al. (19) found that the sensitivity for detecting patients that may develop heart failure increased from 58% to 100%, but this occurred with a concomitant decrease in specificity from 75% to 41%. Thus, to date, stress nuclear assessments of LVEF to identify cardiac injury after receipt of anthracycline are not widely performed.
In addition to systolic dysfunction, LV diastolic function is often assessed with radioisotope-based techniques. Count-time curves, the peak filling rate (PFR), the PFR normalized to stroke volume, and time-to-peak filling rate detected with planar equilibrium radionuclide ventriculography (ERNV) are associated with anthracycline-induced diastolic dysfunction (20, 21) . Reductions in these ERNV measures of LV diastolic function correlate with the simultaneous decreases in LVEF, suggesting that anthracyclines impair both systolic and diastolic function (21) . Moreover, a recent study by Cochet et al. (22) demonstrates that baseline prolongation of time-to-peak filling rate (which reflects impairment of diastolic function before treatment) is an independent predictor for trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
It is important to recognize that although ERNA is widely available for identifying LV dysfunction associated with chemotherapy-related cardiotoxicity (17, 20, 23, 24) , there are limitations to the procedure. First, the procedure exposes patients to an ionizing radiation dose (estimated at 7.8 mSv per examination). This is problematic for childhood cancer patients or those who receive repeated exposures by surveillance protocol guidelines. Second, the procedure produces little information regarding other cardiac parameters such as those related to valvular structure or the pericardial space. Finally, the technique is not well suited for detecting small changes in LVEF or direct measures of myocardial injury that may provide important evidence of early injury that predispose one to future CV events.
In patients with heart failure, the single-photon emission computed tomography (SPECT) and positron emission tomography (PET) techniques using radiolabeled neurotransmitters and receptor ligands have been used to evaluate pre-synaptic reuptake, neurotransmitter storage, and also activity of postsynaptic receptors (25) (26) (27) . Metaiodobenzylguanidine (MIBG) is a quanethidine analog that shares type I adrenergic neuroreceptor uptake storage and release mechanisms throughout the body with norepinephrine (25) (26) (27) . After being labeled with 123 I, uptake of regional 123 I-MIBG reflects neuronal integrity, and its release reflects adrenergic function (25) (26) (27) . Calculation of the heart-to-mediastinum count ratio of 123 I-MIBG uptake and delay in the 4-h post-injection washout rates have been observed in patients with heart failure or those receiving anthracycline-based chemotherapy. Also, a decrease in the heart-tomediastinum count ratio correlated with a higher cumulative dose of anthracycline (27) (28) (29) to 48% are more difficult to obtain with a high degree of certainty (17, 23, 56) . The role of microbubble contrast in assessing cardiac function after treatment for cancer is not well
Kongbundansuk and Hundley Whether existing planning or surveillance images acquired as components of clinical exams used to stage cancer could be used for these purposes requires further study (68) (69) (70) (71) (72) (73) . At present, information related to the CV system is often not reported on Kongbundansuk and Hundley It is important to note that although CMR is accurate and reproducible, it does not expose one to ionizing radiation, and assesses multiple aspects of the CV system in a single exam, its availability is relatively low and is not well suited for use in those with cardiac pacemakers, cardiac resynchronization therapy devices, internal cardiac defibrillators, or intracranial metal. Moreover, in patients with renal insufficiency (estimated glomerular filtration rates #30 ml/min), precaution is needed when gadolinium contrast is considered because of an increased incidence of nephrogenic systemic fibrosis (92).
INVESTIGATIVE NONINVASIVE IMAGING STRATEGIES FOR SCREENING CANCER TREATMENT-RELATED CARDIOTOXICITY
In addition to current clinical applications, there are additional initiatives underway in research venues to image processes involved in cancer therapy-related (Fig. 3) . Importantly, however, the specificity of 111 In-antimyosin scintigraphy is low (25% to 50%) for predicting decrements in LVEF 12 months after receipt of cancer treatment (78) . PET with its ability to quantify myocardial blood flow, oxygen extraction (using 15 O as a tracer), myocardial glucose metabolism, and fatty acid metabolism has been preliminarily investigated regarding the detection of cardiac toxicity after receipt of cancer Table 1 .
Second, the array of current and future imaging metrics (Fig. 4) need to be evaluated in terms of predicting future CV events in patients treated for cancer.
These imaging-related measures need to be evaluated in the context of existing risk factor prediction models for forecasting risk. Are these imaging markers bene- 1045. E-mail: ghundley@wakehealth.edu.
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